Research ExplorerPublicationsGenetic factors that modify the outcome of viral hepatitis

Genetic factors that modify the outcome of viral hepatitis

Standard

Genetic factors that modify the outcome of viral hepatitis. / Stättermayer, A F; Scherzer, T; Beinhardt, S; Rutter, K; Hofer, H; Ferenci, P.

In: ALIMENT PHARM THER, Vol. 39, No. 10, 01.05.2014, p. 1059-70.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Stättermayer, AF, Scherzer, T, Beinhardt, S, Rutter, K, Hofer, H & Ferenci, P 2014, 'Genetic factors that modify the outcome of viral hepatitis', ALIMENT PHARM THER, vol. 39, no. 10, pp. 1059-70. https://doi.org/10.1111/apt.12717

APA

Stättermayer, A. F., Scherzer, T., Beinhardt, S., Rutter, K., Hofer, H., & Ferenci, P. (2014). Genetic factors that modify the outcome of viral hepatitis. ALIMENT PHARM THER, 39(10), 1059-70. https://doi.org/10.1111/apt.12717

Vancouver

Stättermayer AF, Scherzer T, Beinhardt S, Rutter K, Hofer H, Ferenci P. Genetic factors that modify the outcome of viral hepatitis. ALIMENT PHARM THER. 2014 May 1;39(10):1059-70. https://doi.org/10.1111/apt.12717

Bibtex

@article{c08f20107eef4f05b74da7a791024677,
title = "Genetic factors that modify the outcome of viral hepatitis",
abstract = "BACKGROUND: Genetic factors can play an important role for treatment response and disease progression in chronic viral hepatitis.AIM: To review the influence of host genetic factors on the clinical course as well as on treatment response in patients with viral hepatitis.METHODS: Review of the literature.RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-α (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance. A further GWAS demonstrated that ITPA genetic variants protect HCV genotype 1 patients from RBV-induced anaemia. Another polymorphism in the patatin-like phospholipase domain containing 3 (PNPLA3) is associated with hepatic steatosis. Difficult-to-treat hepatitis C patients homozygous for GG had an up to five-fold lower chance of viral clearance on PEG/RBV than non-GG patients. In chronic hepatitis B patients treated with PEG-IFN several retrospective analyses of IL28B rs12980275 and rs12979860 genotypes yielded conflicting results which can be explained by the heterogeneity between the study populations. Some variants of the HLA-DP locus (HLA-DPA1 A allele and HLA-DPB1) protect against progression of chronic hepatitis B infection.CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection. In contrast, so far identified genetic factors play only a minor role in chronic hepatitis B infection.",
keywords = "Antiviral Agents, Drug Therapy, Combination, Genotype, HLA-DP alpha-Chains, HLA-DP beta-Chains, Hepatitis B, Chronic, Hepatitis C, Chronic, Humans, Interferon-alpha, Interleukins, Polyethylene Glycols, Polymorphism, Genetic, Recombinant Proteins, Ribavirin, Treatment Outcome",
author = "St{\"a}ttermayer, {A F} and T Scherzer and S Beinhardt and K Rutter and H Hofer and P Ferenci",
note = "{\textcopyright} 2014 John Wiley & Sons Ltd.",
year = "2014",
month = may,
day = "1",
doi = "10.1111/apt.12717",
language = "English",
volume = "39",
pages = "1059--70",
journal = "ALIMENT PHARM THER",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "10",

}

RIS

TY - JOUR

T1 - Genetic factors that modify the outcome of viral hepatitis

AU - Stättermayer, A F

AU - Scherzer, T

AU - Beinhardt, S

AU - Rutter, K

AU - Hofer, H

AU - Ferenci, P

N1 - © 2014 John Wiley & Sons Ltd.

PY - 2014/5/1

Y1 - 2014/5/1

N2 - BACKGROUND: Genetic factors can play an important role for treatment response and disease progression in chronic viral hepatitis.AIM: To review the influence of host genetic factors on the clinical course as well as on treatment response in patients with viral hepatitis.METHODS: Review of the literature.RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-α (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance. A further GWAS demonstrated that ITPA genetic variants protect HCV genotype 1 patients from RBV-induced anaemia. Another polymorphism in the patatin-like phospholipase domain containing 3 (PNPLA3) is associated with hepatic steatosis. Difficult-to-treat hepatitis C patients homozygous for GG had an up to five-fold lower chance of viral clearance on PEG/RBV than non-GG patients. In chronic hepatitis B patients treated with PEG-IFN several retrospective analyses of IL28B rs12980275 and rs12979860 genotypes yielded conflicting results which can be explained by the heterogeneity between the study populations. Some variants of the HLA-DP locus (HLA-DPA1 A allele and HLA-DPB1) protect against progression of chronic hepatitis B infection.CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection. In contrast, so far identified genetic factors play only a minor role in chronic hepatitis B infection.

AB - BACKGROUND: Genetic factors can play an important role for treatment response and disease progression in chronic viral hepatitis.AIM: To review the influence of host genetic factors on the clinical course as well as on treatment response in patients with viral hepatitis.METHODS: Review of the literature.RESULTS: A landmark genome-wide association study (GWAS) identified polymorphisms in the IL28B gene on chromosome 19 (19q13.13) associated with response to therapy with pegylated interferon-α (PEG-IFN) and ribavirin (RBV) and spontaneous viral clearance in acute hepatitis C. Furthermore, IL28B genotype is associated with changes of lipid metabolism and insulin resistance. A further GWAS demonstrated that ITPA genetic variants protect HCV genotype 1 patients from RBV-induced anaemia. Another polymorphism in the patatin-like phospholipase domain containing 3 (PNPLA3) is associated with hepatic steatosis. Difficult-to-treat hepatitis C patients homozygous for GG had an up to five-fold lower chance of viral clearance on PEG/RBV than non-GG patients. In chronic hepatitis B patients treated with PEG-IFN several retrospective analyses of IL28B rs12980275 and rs12979860 genotypes yielded conflicting results which can be explained by the heterogeneity between the study populations. Some variants of the HLA-DP locus (HLA-DPA1 A allele and HLA-DPB1) protect against progression of chronic hepatitis B infection.CONCLUSIONS: The determination of IL28B polymorphisms may be useful to individualise treatment options when using PEG/RBV based therapies for chronic hepatitis C infection. In contrast, so far identified genetic factors play only a minor role in chronic hepatitis B infection.

KW - Antiviral Agents

KW - Drug Therapy, Combination

KW - Genotype

KW - HLA-DP alpha-Chains

KW - HLA-DP beta-Chains

KW - Hepatitis B, Chronic

KW - Hepatitis C, Chronic

KW - Humans

KW - Interferon-alpha

KW - Interleukins

KW - Polyethylene Glycols

KW - Polymorphism, Genetic

KW - Recombinant Proteins

KW - Ribavirin

KW - Treatment Outcome

U2 - 10.1111/apt.12717

DO - 10.1111/apt.12717

M3 - SCORING: Journal article

C2 - 24654629

VL - 39

SP - 1059

EP - 1070

JO - ALIMENT PHARM THER

JF - ALIMENT PHARM THER

SN - 0269-2813

IS - 10

ER -